ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA biopharma began operations in 2005 and is headquartered in Broomfield, Colorado.
The Company’s lead investigational product is Gencaro™ 1 (bucindolol hydrochloride), a genetically-targeted beta-blocker with unique pharmacology, in development for heart failure and other indications. ARCA’s New Drug Application for Gencaro for chronic heart failure, was accepted for filing by the U.S. Food and Drug Administration in September, 2008, and is currently under review by the FDA with a Prescription Drug User Fee Act (PDUFA) date of May 31, 2009.
ARCA biopharma is positioned to bring personalized therapies forthe treatment of cardiovascular disease, through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. Applying this approach to the development of Gencaro, ARCA scientists have discovered genetic variations in two cardiac receptors that interact with Gencaros unique pharmacology. ARCA biopharma believes that these variations have the potential to help predict patient response to Gencaro.
Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company will market its products in the U.S. through its own sales force, and plans to commercialize in ex-U.S. territories through partnerships.
In January, 2009, ARCA biopharma merged with Nuvelo, Inc., forming a new cardiovascular company with increased resources, expertise, and a significant developmental pipeline. ARCA biopharma, Inc. trades on the Nasdaq Global Market, under the symbol ABIO.
1. Gencaro tradename is also under review with the FDA.
